Drug
Resmetirom clinical trials
Also written MGL-3196 and VIA-3196.
Keep track of what changes. Save the resmetirom studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 1
Madrigal Pharmaceuticals, Inc. (20) · Sagimet Biosciences Inc. (1) · Naga P. Chalasani (1) · Nabiqasim Industries (Pvt) Ltd (1)
Often tested with
Tested in the same studies.
Pioglitazone (2) · TVB-2640 (1) · Simvastatin (1) · Rosuvastatin (1) · Clopidogrel (1) · Atorvastatin (1) · Dapagliflozin (1)
Studies
Open first, then newest update. How each study uses resmetirom is read from its arms, and is right about nine times in ten.
Testing it · 23
- Resmetirom in Patients With MASH and HFpEFRecruitingPhase 1Madrigal Pharmaceuticals, Inc.NCT07830758Written as Resmetirom
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingPhase 4Madrigal Pharmaceuticals, Inc.NCT07848191Written as Rezdiffra
- Study of Resmetirom in Children and Adolescents With MASHRecruitingPhase 2Madrigal Pharmaceuticals, Inc.NCT07763015Written as Resmetirom
- Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHRecruitingPhase 2Madrigal Pharmaceuticals, Inc.NCT07335601Written as Resmetirom
- A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIVRecruitingPhase 2Naga P. ChalasaniNCT07143968Written as Resmetirom
- Resmiterom Efficacy & Safety in Patients With MASHRecruitingPhase 4Nabiqasim Industries (Pvt) LtdNCT07249788Written as Resmetirom
- A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Active, not recruitingPhase 3Madrigal Pharmaceuticals, Inc.NCT05500222Written as Resmetirom
- Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedPhase 2Madrigal Pharmaceuticals, Inc.NCT03038022Written as MGL-3196 (resmetirom)
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisActive, not recruitingPhase 3Madrigal Pharmaceuticals, Inc.NCT03900429Written as MGL-3196
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Active, not recruitingPhase 3Madrigal Pharmaceuticals, Inc.NCT04951219Written as Resmetirom
- A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult ParticipantsCompletedPhase 1Sagimet Biosciences Inc.NCT07216313Written as Resmetirom
- Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2Madrigal Pharmaceuticals, Inc.NCT02912260Written as MGL-3196
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT06397872Written as 100 mg Resmetirom Tablet
- Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT04643795Written as MGL-3196
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsCompletedPhase 3Madrigal Pharmaceuticals, Inc.NCT04197479Written as Resmetirom
- Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT01367873Written as VIA-3196
- Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT02542969Written as MGL-3196
- Drug Interaction Study of MGL-3196 With ClopidogrelCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT04671069Written as MGL-3196
- Drug Interaction Study of MGL-3196 With PioglitazoneCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT04671056Written as MGL-3196
- Bioavailability Study of MGL-3196 Tablets Compared to CapsulesCompletedPhase 1Madrigal Pharmaceuticals, Inc.NCT03413124Written as MGL-3196 Tablet
Codes
What other systems call resmetirom · ClinicalTrials.gg INT006493
- MeSH (NLM) C588408resmetiromConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RE0V0T1ES0RESMETIROMConfirmed FDA, NLM, Wikidata
- Wikidata Q27288071resmetiromConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170368ResmetiromOne source FDA
- DrugBank DB12914One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C588408 | resmetirom | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RE0V0T1ES0 | RESMETIROM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27288071 | resmetirom | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170368 | Resmetirom | One source FDA |
| DrugBank | DB12914 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.